Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 in Early Parkinson's Disease
NCT04629404Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Pharmacodynamic Measures at Day 50 and Safety Measures at Day 50. Started Nov 2018; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04629404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629404.